We are live on ! Find out more
MGNX icon

MacroGenics

128 hedge funds and large institutions have $182M invested in MacroGenics in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 19

11% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 37

3% more funds holding

Funds holding: 124128 (+4)

0.56% more ownership

Funds ownership: 88.89%89.45% (+0.56%)

3% less capital invested

Capital invested by funds: $188M → $182M (-$5.41M)

73% less call options, than puts

Call options by funds: $174K | Put options by funds: $644K

Holders
128
Holders Change
+4
Holders Change %
+3.23%
% of All Funds
1.68%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
41
Reduced
37
Closed
19
Calls
$174K
Puts
$644K
Net Calls
-$470K
Net Calls Change
-$792K

MGNX Hedge Fund Activity: Q4 2024 in Review

128 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q4 2024, worth a combined $182M — down 2.9% from $188M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new MGNX positions and 19 closed out — a net gain of 4 holders — while 41 added to existing stakes and 37 trimmed.

The largest buyer was Wasatch Advisors, adding an estimated $3.43M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.77M.

  • 128 institutional investors held MacroGenics (MGNX) as of Q4 2024, up from 124 in Q3 2024.
  • Funds reported $182M of MacroGenics stock for Q4 2024, down 2.9% quarter-over-quarter.
  • 23 funds opened new MacroGenics positions in Q4 2024 and 19 closed out, a net change of +4 holders.
  • The largest MacroGenics buyer in Q4 2024 was Wasatch Advisors, an estimated $3.43M added.
  • The largest MacroGenics seller in Q4 2024 was T. Rowe Price Associates, an estimated $2.77M sold.

Based on aggregated 13F filings for Q4 2024.